Inhibitors of the HSP90 Molecular Chaperone: Current Status
- 1 January 2006
- book chapter
- Published by Elsevier
- Vol. 95, 323-348
- https://doi.org/10.1016/s0065-230x(06)95009-x
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Hsp90 Inhibitors Identified from a Library of Novobiocin AnaloguesJournal of the American Chemical Society, 2005
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced MalignanciesJournal of Clinical Oncology, 2005
- Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Blood, 2005
- Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasivenessNature Cell Biology, 2004
- Structure of the N-terminal Domain of GRP94Journal of Biological Chemistry, 2003
- Hsp90: Chaperoning signal transductionJournal of Cellular Physiology, 2001
- The Hallmarks of CancerCell, 2000
- GRP94, an ER chaperone with protein and peptide binding propertiesSeminars in Cell & Developmental Biology, 1999
- Labeling of v‐Src and BCR‐ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanismFEBS Letters, 1994
- Clinical and biological significance of HSP89 alpha in human breast cancerInternational Journal of Cancer, 1992